Lumos Pharma, Inc. (LUMO)

Market Cap	21.24M
Revenue (ttm)	2.05M
Net Income (ttm)	-34.03M
Shares Out	8.11M
EPS (ttm)	-4.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,347
Open	2.450
Previous Close	2.460
Day's Range	2.410 - 2.760
52-Week Range	2.410 - 4.550
Beta	0.35
Analysts	Strong Buy
Price Target	18.00 (+587.02%)
Earnings Date	May 1, 2024

About LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: LUMO

Financial Performance

In 2023, Lumos Pharma's revenue was $2.05 million, an increase of 34.67% compared to the previous year's $1.52 million. Losses were -$34.03 million, 9.57% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for LUMO stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 587.02% from the latest price.

Price Target

$18.0

(587.02% upside)

Analyst Consensus: Strong Buy